These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31828091)

  • 1. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
    Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
    Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
    Tang J; Gui C; Qiu S; Wang M
    World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
    Ren N; Tian Z; Sun H; Lu X
    Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of multifocality in papillary thyroid carcinoma.
    Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
    Che X; Zhang G; Zhang X; Xue J
    Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A-kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients.
    Zhang L; Tao H; Ke K; Ma C
    J Clin Lab Anal; 2020 Oct; 34(10):e23452. PubMed ID: 32643206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
    Chen X; Jin J; Zheng L; Sheng Y; Sun J
    J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
    Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
    Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
    Xu W; Wang L; An Y; Ye J
    Med Sci Monit; 2019 May; 25():3762-3770. PubMed ID: 31107859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
    Xing Y; Luo DY; Long MY; Zeng SL; Li HH
    World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
    Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
    Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
    Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
    Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 "SLC34A2" in Papillary Thyroid Carcinoma: An Immunohistochemical Study.
    Hakim SA; Abd El Atti RM; Faheim RM; Abou Gabal HH
    Anal Cell Pathol (Amst); 2021; 2021():3198555. PubMed ID: 34336552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
    Akslen LA; Varhaug JE
    Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
    Ahn HY; Song RY; Ahn HS; Kim HS
    Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
    Wu Y; Li J; Wu X; Dai L
    Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.
    Wen S; Luo Y; Wu W; Zhang T; Yang Y; Ji Q; Wu Y; Shi R; Ma B; Xu M; Qu N
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1579-1589. PubMed ID: 34693452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.